Latest news
VRDN: FDA approval and launch of Lumvoa, plus strong cash position, drive commercial and R&D momentum - TradingViewTradingView · Thu, 06 Aug 2026 11:15:35 GMTViridian Therapeutics reports Q2 2026 net loss of $127.1M, cash $981.5M after Lumvoa FDA approval - TradingViewTradingView · Thu, 06 Aug 2026 11:13:01 GMT